The biology and therapeutic targeting of the proprotein convertases

被引:671
作者
Seidah, Nabil G. [1 ]
Prat, Annik [1 ]
机构
[1] Univ Montreal, Biochem Neuroendocrinol Lab, Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada
基金
加拿大健康研究院;
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; ELEMENT-BINDING-PROTEIN; REDUCES LDL-CHOLESTEROL; MICE LACKING; SITE-1; PROTEASE; IN-VITRO; PROHORMONE CONVERTASES; PROCESSING ENZYME; ANTHRAX TOXIN; PCSK9; GENE;
D O I
10.1038/nrd3699
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 090105 [作物生产系统与生态工程];
摘要
The mammalian proprotein convertases constitute a family of nine secretory serine proteases that are related to bacterial subtilisin and yeast kexin. Seven of these (proprotein convertase 1 (PC1), PC2, furin, PC4, PC5, paired basic amino acid cleaving enzyme 4 (PACE4) and PC7) activate cellular and pathogenic precursor proteins by cleavage at single or paired basic residues, whereas subtilisin kexin isozyme 1 (SKI-1) and proprotein convertase subtilisin kexin 9 (PCSK9) regulate cholesterol and/or lipid homeostasis via cleavage at non-basic residues or through induced degradation of receptors. Proprotein convertases are now considered to be attractive targets for the development of powerful novel therapeutics. In this Review, we summarize the physiological functions and pathological implications of the proprotein convertases, and discuss proposed strategies to control some of their activities, including their therapeutic application and validation in selected disease states.
引用
收藏
页码:367 / 383
页数:17
相关论文
共 243 条
[1]
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].
Abifadel, M ;
Varret, M ;
Rabès, JP ;
Allard, D ;
Ouguerram, K ;
Devillers, M ;
Cruaud, C ;
Benjannet, S ;
Wickham, L ;
Erlich, D ;
Derré, A ;
Villéger, L ;
Farnier, M ;
Beucler, I ;
Bruckert, E ;
Chambaz, J ;
Chanu, B ;
Lecerf, JM ;
Luc, G ;
Moulin, P ;
Weissenbach, J ;
Prat, A ;
Krempf, M ;
Junien, C ;
Seidah, NG ;
Boileau, C .
NATURE GENETICS, 2003, 34 (02) :154-156
[2]
Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease [J].
Abifadel, Marianne ;
Rabes, Jean-Pierre ;
Devillers, Martine ;
Munnich, Arnold ;
Erlich, Daniele ;
Junien, Claudine ;
Varret, Mathilde ;
Boileau, Catherine .
HUMAN MUTATION, 2009, 30 (04) :520-529
[3]
The pore-forming toxin proaerolysin is activated by furin [J].
Abrami, L ;
Fivaz, M ;
Decroly, E ;
Seidah, NG ;
Jean, F ;
Thomas, G ;
Leppla, SH ;
Buckley, JT ;
van der Goot, FG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (49) :32656-32661
[4]
ANDERSON ED, 1993, J BIOL CHEM, V268, P24887
[5]
MECHANISMS OF DISEASE Proprotein Convertases in Health and Disease [J].
Artenstein, Andrew W. ;
Opal, Steven M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2507-2518
[6]
Dual regulation of the LDL receptor - Some clarity and new questions [J].
Attie, AD ;
Seidah, NG .
CELL METABOLISM, 2005, 1 (05) :290-292
[7]
Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial [J].
Awan, Zuhier ;
Seidah, Nabil G. ;
MacFadyen, Jean G. ;
Benjannet, Suzanne ;
Chasman, Daniel I. ;
Ridker, Paul M. ;
Genest, Jacques .
CLINICAL CHEMISTRY, 2012, 58 (01) :183-189
[8]
Enzymic characterization in vitro of recombinant proprotein convertase PC4 [J].
Basak, A ;
Touré, BB ;
Lazure, C ;
Mbikay, M ;
Chrétien, M ;
Seidah, NG .
BIOCHEMICAL JOURNAL, 1999, 343 :29-37
[9]
In vitro elucidation of substrate specificity and bioassay of proprotein convertase 4 using intrarnolecularly quenched fluorogenic peptides [J].
Basak, S ;
Chrétien, M ;
Mbikay, M ;
Basak, A .
BIOCHEMICAL JOURNAL, 2004, 380 :505-514
[10]
Proprotein Convertase Inhibition Results in Decreased Skin Cell Proliferation, Tumorigenesis, and Metastasis [J].
Bassi, Daniel E. ;
Zhang, Jirong ;
Cenna, Jonathan ;
Litwin, Samuel ;
Cukierman, Edna ;
Klein-Szanto, Andres J. P. .
NEOPLASIA, 2010, 12 (07) :516-U24